Taberbovermine B






Names

    • Taberbovermine B

Attributes

  • Canonical SMILES

    COC1=CC3=C(NC2=C(C(OC)=O)C[C@@](C5)(CC)[C@H]4[C@@]23CCN4C5=O)C=C1OC

  • InChI

    InChI=1S/C22H26N2O5/c1-5-21-10-12(19(26)29-4)18-22(6-7-24(20(21)22)17(25)11-21)13-8-15(27-2)16(28-3)9-14(13)23-18/h8-9,20,23H,5-7,10-11H2,1-4H3/t20-,21+,22+/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 77.10000000000001
  • #RotBonds: 4
  • MW: 398.4590000000002
  • HBD: 1
  • HBA: 6
  • logP: 2.5989000000000004
  • Chemical Formula: C22H26N2O5


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. bovina China - Cai20170612

External Databases


References

  • Diverse aspidosperma-type alkaloids from the leaves of Tabernaemontana bovina with anti-hepatoma activity. Fitoterapia, 2023 (PMID 37336417).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Antihepatoma
    • Cytotoxicity

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.99
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.95
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -2.44
    Distribution Blood-Brain Barrier (Central Nervous System) -2.89
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.63
    Plasma Protein Binding 58.85
    Steady State Volume of Distribution 1.63
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 5.63
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -0.53
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.11
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 4.6
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -35.16
    Rat (Acute) 2.81
    Rat (Chronic Oral) 2.32
    Fathead Minnow 3.99
    Respiratory Disease Safe
    Skin Sensitisation Safe
    SR-ATAD5 Toxic
    SR-ARE Toxic
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Toxic
    General Properties Boiling Point 460.51
    Hydration Free Energy -4.32
    Log(D) at pH=7.4 2.17
    Log(P) 2.21
    Log S -3.06
    Log(Vapor Pressure) -7.87
    Melting Point 218.2
    pKa Acid 8.19
    pKa Basic 6.33